FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113048649> ?p ?o ?g. }

• W2113048649 endingPage "200" @default.
• W2113048649 startingPage "199" @default.
• W2113048649 abstract "HomeHypertensionVol. 41, No. 2Hypertension, Platelets, and the Endothelium Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBHypertension, Platelets, and the EndotheliumThe “Thrombotic Paradox” of Hypertension (or “Birmingham Paradox”) Revisited Gregory Y.H. Lip Gregory Y.H. LipGregory Y.H. Lip From the Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, England. Search for more papers by this author Originally published1 Feb 2003https://doi.org/10.1161/01.HYP.0000049761.98155.7BHypertension. 2003;41:199–200Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: February 3, 2003: Previous Version 1 Platelets are the smallest of the blood cells, yet they are one of the main players during the process of thrombus formation (thrombogenesis). Furthermore, the traditional belief that the endothelium exists simply to provide an inert interface between the blood and the vessel wall is no longer accurate. Indeed, the endothelium produces a large number of substances that affect blood flow and in turn are affected by changes in the blood and the pressure of blood flow.Despite many therapeutic advances that have lead to increasingly effective antihypertensive drug treatments, the precise pathophysiological mechanisms of hypertension and its complications are still poorly understood. In hypertension, the delicate balance between the vasodilators and the vasoconstrictors is upset, leading to changes that then take place in the vascular beds, setting up a vicious cycle that further maintains the high blood pressure. There is also increasing evidence that platelets and the endothelium, which both get activated in hypertension, have a crucial role in the increased thrombotic tendency seen in hypertension. Indeed, despite exposure of the blood vessels to high pressures, the main complications of hypertension (that is, myocardial infarction and stroke) are paradoxically thrombotic in nature rather than hemorrhagic—“the thrombotic paradox of hypertension” or “Birmingham paradox.” Certainly, increasing clinical and laboratory evidence suggests that hypertension per se may confer a prothrombotic or hypercoagulable state, with abnormalities of coagulation, platelets, and the endothelium—in fulfillment of Virchow’s triad for thrombogenesis.1The processes of thrombogenesis and atherogenesis are also intimately related. Many components of the coagulation and fibrinolytic pathways are primary and secondary predictors of cardiovascular events.2 The close association of these markers with cardiac outcomes and common cardiovascular risk factors raises the distinct possibility that such indices are not merely markers or consequences of thrombosis, but may significantly contribute to the pathogenesis of arterial thrombotic disease.In this issue of Hypertension, Preston et al3 report on the presence of circulating endothelial and platelet microparticles in hypertension. Based on this cross-sectional study of 24 severe hypertensives, 19 mild hypertensives, and 16 control subjects, they suggest that these markers may be useful and specific for pressure-induced endothelial and platelet activation in hypertension. These micro-particles may also play a pathogenic role in mediating target organ injury in severe hypertension.Although these indices are associated with blood pressure, a relationship to hypertensive target organ damage or prognosis should convincingly be present, and these indices should also be favorably altered by therapy.1 Preston et al3 classify their hypertensive patient groups based on diastolic blood pressure in patients admitted to the emergency department, because diastolic blood pressure was used in triage guidelines. Certainly, it is well established that systolic blood pressure is the better predictor of cardiovascular risk, even after adjusting for underlying diastolic blood pressure,4 and indeed, patients with isolated systolic hypertension exhibit similar abnormalities of the prothrombotic state compared with patients with systolic-diastolic hypertension.5 The possibility also remains that the high diastolic blood pressures in the emergency room were a “white coat effect”; 24-hour ambulatory blood pressure monitoring (ABPM) would have established a much better relation to blood pressure “load.” In fact, 24-hour ABPM has been correlated to target organ damage.6 However, Preston et al3 did find significant correlations between circulating endothelial and platelet microparticles and systolic blood pressure.Nevertheless, target organ damage is not examined in the present paper by Preston et al.3 The typical surrogate indices of hypertensive target organ damage, such as left ventricular hypertrophy and microalbuminuria (defined as the excretion of urine albumin between 20 and 200 μg/min), have been shown to have a modest correlation to some markers of endothelial damage/dysfunction, such as von Willebrand factor (vWf) levels.7,8 In a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), Spencer et al9 recently showed that patients with hypertensive target organ damage had significantly higher plasma vWf, but there were no statistically significant differences in platelet count or soluble P-selectin (an index of platelet activation) between those with and those without target organ damage. Importantly, vWf levels were still a significant independent predictor of target organ damage on multivariate analysis, and intensified cardiovascular risk factor management (including blood pressure reduction) resulted in improvements in indices of hemorheology and endothelial and platelet function.Preston et al3 may be using circulating endothelial and platelet microparticles as “novel” indices of endothelial and platelet activation, but a very important aspect would be a comparison with established markers of endothelial and platelet activation. In their study, endothelial microparticles (supposedly an endothelial marker) correlate more strongly with platelet CD62 (a platelet marker, r=0.36 and P=0.005) than with other established endothelial markers (vWf, soluble intercellular adhesion molecule-1 [sICAM-1], and soluble vascular cell adhesion molecule-1 [sVCAM-1]) that were studied. In fact, the only significant correlation between endothelial microparticles and sVCAM-1 was weak (r=0.26, P=0.04). Similarly, platelet microparticles (supposedly a platelet marker) did not correlate significantly with platelet CD62 (r=0.025, P=0.054), and if platelet microparticles truly reflected platelet activation, a better relationship would be preferred. This paradox raises issues about how valid these new indices are as endothelial and platelet markers. On a broader perspective, this issue highlights a long-standing problem: how best to measure or quantify abnormalities of platelets and the endothelium?In general, the quantification of platelet abnormalities can be performed using a wide variety of measures, such as platelet volume, aggregometry, excretion of metabolites, flow cytometry to detect various platelet antigens, and the measurement of increased plasma levels of platelet-specific products, such as platelet factor 4, β-thromboglobulin (BTG), and the soluble adhesion molecule P-selectin.10 The choice of method may sometimes depend on the nature of the study. As an example, measurement of large numbers, say, in epidemiological studies may require the use of plasma markers rather than the more specialized, time-consuming techniques such as flow-cytometry.Similarly, debate remains over how best to assess the endothelium. Various indices have been used to assess endothelial activation, dysfunction, and damage. The ideal one must not only be specific to the endothelium but must also be stable and easily measurable.11 Indeed, the “gold standard” still remains uncertain, as available indices quantify different aspects of endothelial physiology. In addition, words such as “damage,” “injury,” “dysfunction,” and “activation” are currently freely used in the study of the endothelium without a clear definition of, or even a consensus about, their meanings. A continuum is also likely to exist among endothelial activation (eg, by cytokines), endothelial dysfunction (resulting in thrombogenesis and atherogenesis), and endothelial damage (resulting in overt vascular damage and atherosclerosis). Endothelial (dys)function also implies some functional component to the endothelium, which may be rather different from that assessed by measurement of plasma markers or endothelial microparticles.Therefore, are endothelial and platelet microparticles3 really a reflection of endothelial and platelet damage rather than activation, or are we simply detecting (platelet or endothelial?) cell debris from a severely damaged vascular tree? One could argue that perhaps the best proof of endothelial damage would be to observe desquamated, but not apoptotic, endothelial cells in circulating blood. A method to capture these cells has been developed and used to prove that endothelial injury occurs in acute myocardial infarction and unstable angina (but not in stable angina), confirming a separate mechanism in pathogenesis.12 Increased surface expression of markers such as E-selectin is probably a reflection of endothelial activation, rather than damage, and E-selectin is not expressed by normal resting endothelial cells.13Lastly, many of the patients in the study by Preston et al3 were previously taking antihypertensive drugs, and the “hangover” effect of these drugs may possibly be a confounder. Antihypertensive drugs may partly act by influencing both the coagulation and fibrinolytic systems in hypertension, adding to their protective potential with respect to cardiovascular end points. Beyond their blood pressure–lowering potential, some antihypertensive agents also exhibit a number of nonhemodynamic effects, such as changes in serum electrolytes, lipids and carbohydrate metabolism, endothelial function, vascular smooth muscles, cardiomyocyte growth, and, possibly, fibrinolysis.14 Do different antihypertensive drugs differentially affect the endothelium or platelets, and if so, does it affect activation, (dys)function, or the integrity/damage of these cells? With a new technique to assess the endothelium and platelets in hypertension, we still need further large-scale comparisons with established methods of assessment, data on the relation to target organ damage and the effects of treatment, and a definition of which aspect of cellular pathophysiology we are studying (and why!).The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.We acknowledge the support of the City Hospital Research and Development program for the Hemostasis, Thrombosis, and Vascular Biology Unit.FootnotesCorrespondence to Professor G.Y.H. Lip, Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, England. E-mail [email protected] References 1 Lip GYH. Hypertension and the prothrombotic state. J Hum Hypertens. 2000; 14: 687–990.CrossrefMedlineGoogle Scholar2 Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994; 343: 940–943.CrossrefMedlineGoogle Scholar3 Preston RA, Jy W, Jimenez JJ, Mauro LM, Horstman LL, Valle M, Aime G, Ahn YS. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension. 2003; 41: 211–217.LinkGoogle Scholar4 Tin LL, Beevers DG, Lip GYH. Systolic vs diastolic blood pressure and the burden of hypertension. J Hum Hypertens. 2002; 16: 147–150.CrossrefMedlineGoogle Scholar5 Lip GYH, Blann AD, Beevers DG. Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic-diastolic hypertension. J Hypertens. 1999; 17: 1203–1207.CrossrefMedlineGoogle Scholar6 Cuspidi C, Macca G, Sampieri L, Fusi V, Severgnini B, Michev I, Salerno M, Magrini F, Zanchetti A. Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. J Hypertens. 2001; 19: 1539–1545.CrossrefMedlineGoogle Scholar7 Lip GYH, Blann AD, Jones AF, Lip PL, Beevers DG. Relationship of endothelium, thrombogenesis, and haemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol. 1997; 80: 1566–1571.CrossrefMedlineGoogle Scholar8 Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell’Omo G, Catapano G, Matteucci E, Talarico L, Morale M, De Negri F. Microalbuminuria and endothelial dysfunction inessential hypertension. Lancet. 1994; 344: 14–18.CrossrefMedlineGoogle Scholar9 Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GYH. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension. 2002; 40: 61–66.LinkGoogle Scholar10 Kamath S, Blann AD, Lip GYH. Platelet activation: assessment and quantification. Eur Heart J. 2001; 22: 1561–1571.CrossrefMedlineGoogle Scholar11 Blann AD, Lip GYH. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul Fibrinolysis. 1998; 9: 297–306.CrossrefMedlineGoogle Scholar12 Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood. 1999; 93: 2951–2958.CrossrefMedlineGoogle Scholar13 Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun. 1992; 187: 584–89.CrossrefMedlineGoogle Scholar14 Lee AJ. The role of rheology and haemostatic factors in hypertension. J Human Hypertens. 1997; 11: 767–776.CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Xu Y and Guo Y (2023) Platelet indices and blood pressure: a multivariable mendelian randomization study, Thrombosis Journal, 10.1186/s12959-023-00475-6, 21:1 Dandamudi A, Seibel W, Tourdot B, Cancelas J, Akbar H and Zheng Y (2023) Structure–Activity Relationship Analysis of Rhosin, a RhoA GTPase Inhibitor, Reveals a New Class of Antiplatelet Agents, International Journal of Molecular Sciences, 10.3390/ijms24044167, 24:4, (4167) Xu J, Zeng R, Zhang Y, Lin S, Tan J, Zhu H, Mai X, Guo L and Zhang M (2023) Systemic inflammation markers and the prevalence of hypertension: A NHANES cross-sectional study, Hypertension Research, 10.1038/s41440-023-01195-0 Li J, Tong D, Song B, Xie F, Zhang G, Hao X, Li W, Chi H, Wang W and Shao Y (2022) Inflammatory cytokines induce neutrophil extracellular traps interaction with activated platelets and endothelial cells exacerbate coagulation in moderate and severe essential hypertension, Journal of Hypertension, 10.1097/HJH.0000000000003250, 40:11, (2219-2229), Online publication date: 1-Nov-2022. Chiu P, Chattopadhyay A, Wu M, Hsiao T, Lin C and Lu T (2021) Elucidation of a Causal Relationship Between Platelet Count and Hypertension: A Bi-Directional Mendelian Randomization Study, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.743075, 8 Li J, Tong D, Chen F, Song B, Wang Y, Liu Y, Zhang X, Liu N, Xu Y, Li Y, Yin X and Liu W (2020) Inflammatory cytokines enhance procoagulant activity of platelets and endothelial cells through phosphatidylserine exposure in patients with essential hypertension, Journal of Thrombosis and Thrombolysis, 10.1007/s11239-020-02342-x, 51:4, (933-940), Online publication date: 1-May-2021. Hadiyanti N, Hasmono D and Islam M (2018) Analysis of Differences of Serum Thromboxane B2 Level after Taking Acetosal in Acute Thrombotic Stroke with Diabetes Mellitus and Non-Diabetes Mellitus, Folia Medica Indonesiana, 10.20473/fmi.v54i1.8053, 54:1, (53) Ćujić N, Kardum N, Šavikin K, Zdunić G, Janković T and Menković N (2018) Potential of Chokeberry ( Aronia Melanocarpa L.) as a Therapeutic Food Therapeutic Foods, 10.1016/B978-0-12-811517-6.00007-6, (209-237), . Kardum N, Konic Ristic A, Zec M, Kojadinovic M, Petrovic-Oggiano G, Zekovic M, Kroon P and Glibetić M (2017) Design, formulation and sensory evaluation of a polyphenol-rich food placebo: an example of aronia juice for food intervention studies, International Journal of Food Sciences and Nutrition, 10.1080/09637486.2017.1283682, 68:6, (742-749), Online publication date: 18-Aug-2017. George R, Bhatt A, Narayani J, Thulaseedharan J, Sivadasanpillai H and Tharakan J (2016) Enhanced P-selectin expression on platelet-a marker of platelet activation, in young patients with angiographically proven coronary artery disease, Molecular and Cellular Biochemistry, 10.1007/s11010-016-2756-4, 419:1-2, (125-133), Online publication date: 1-Aug-2016. Freitas-Silva M, Gonçalves L, Medeiros R and Nunes J (2015) Can the Previous Therapeutic Control of the Main Risk Factors of Cerebrovascular Disease Influence the Acetylsalicylic Acid–Nonresponsive Status in Acute Ischemic Stroke Patients? Results from a Portuguese Prospective Cohort Study, Journal of Stroke and Cerebrovascular Diseases, 10.1016/j.jstrokecerebrovasdis.2015.02.021, 24:6, (1383-1389), Online publication date: 1-Jun-2015. Winter R, Sedacca C, Adams A and Orton E (2012) Aortic thrombosis in dogs: Presentation, therapy, and outcome in 26 cases, Journal of Veterinary Cardiology, 10.1016/j.jvc.2012.02.008, 14:2, (333-342), Online publication date: 1-Jun-2012. Fraga-Silva R, Da Silva D, Montecucco F, Mach F, Stergiopulos N, da Silva R and Santos R (2017) The Angiotensin-Converting Enzyme 2/Angiotensin-(1–7)/Mas receptor axis: A potential target for treating thrombotic diseases, Thrombosis and Haemostasis, 10.1160/TH12-06-0396, 108:12, (1089-1096), . Fraga-Silva R, Costa-Fraga F, De Sousa F, Alenina N, Bader M, Sinisterra R and Santos R (2011) An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect, Clinics, 10.1590/S1807-59322011000500021, 66:5, (837-841), Online publication date: 1-Jan-2011. Celi A, Cianchetti S, Dell’Omo G and Pedrinelli R (2014) Angiotensin II, tissue factor and the thrombotic paradox of hypertension, Expert Review of Cardiovascular Therapy, 10.1586/erc.10.161, 8:12, (1723-1729), Online publication date: 1-Dec-2010. PATEL J, TRACEY I, HUGHES E and LIP G (2010) Omega‐3 polyunsaturated acids and cardiovascular disease: notable ethnic differences or unfulfilled promise?, Journal of Thrombosis and Haemostasis, 10.1111/j.1538-7836.2010.03956.x, 8:10, (2095-2104), Online publication date: 1-Oct-2010. Yang P, Liu Y, Yang L, Wei Q and Zeng H (2010) Mechanism and Clinical Significance of the Prothrombotic State in Patients With Essential Hypertension, Clinical Cardiology, 10.1002/clc.20719, 33:6, (E81-E86), Online publication date: 1-Jun-2010. Fraga-Silva R, Sorg B, Wankhede M, deDeugd C, Jun J, Baker M, Li Y, Castellano R, Katovich M, Raizada M and Ferreira A (2010) ACE2 Activation Promotes Antithrombotic Activity, Molecular Medicine, 10.2119/molmed.2009.00160, 16:5-6, (210-215), Online publication date: 1-May-2010. Subramaniam V and Lip G (2014) Hypertension to heart failure: a pathophysiological spectrum relating blood pressure, drug treatments and stroke, Expert Review of Cardiovascular Therapy, 10.1586/erc.09.43, 7:6, (703-713), Online publication date: 1-Jun-2009. Pastor-Pérez F and Marín F (2008) Hypertension, aortic sclerosis and the prothrombotic state: understanding the complex interaction, Journal of Human Hypertension, 10.1038/jhh.2008.103, 23:4, (287-288), Online publication date: 1-Apr-2009. Sechi L, Novello M, Colussi G, Di Fabio A, Chiuch A, Nadalini E, Casanova-Borca A, Uzzau A and Catena C (2008) Relationship of Plasma Renin With a Prothrombotic State in Hypertension: Relevance for Organ Damage, American Journal of Hypertension, 10.1038/ajh.2008.293, 21:12, (1347-1353), Online publication date: 1-Dec-2008. Varughese G, Patel J, Tomson J, Blann A, Hughes E and Lip G (2007) Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial, Journal of Internal Medicine, 10.1111/j.1365-2796.2007.01770.x, 261:4, (384-391), Online publication date: 1-Apr-2007. Boos C, Beevers G and Lip G (2009) Assessment of platelet activation indices using the ADVIA TM 120 amongst ‘high‐risk’ patients with hypertension , Annals of Medicine, 10.1080/07853890601040063, 39:1, (72-78), Online publication date: 1-Jan-2007. Varughese G and Lip G (2007) Platelet and Coagulation Abnormalities Comprehensive Hypertension, 10.1016/B978-0-323-03961-1.50024-6, (223-227), . Dielis A, Smid M, Spronk H, Hamulyak K, Kroon A, ten Cate H and de Leeuw P (2005) The Prothrombotic Paradox of Hypertension, Hypertension, 46:6, (1236-1242), Online publication date: 1-Dec-2005. Varughese G and Lip G (2005) Is hypertension a prothrombotic state?, Current Hypertension Reports, 10.1007/s11906-005-0005-4, 7:3, (168-173), Online publication date: 1-Jun-2005. Arikan E and Sen S (2016) Endothelial Damage and Hemostatic Markers in Patients with Uncomplicated Mild-to-Moderate Hypertension and Relationship with Risk Factors, Clinical and Applied Thrombosis/Hemostasis, 10.1177/107602960501100204, 11:2, (147-159), Online publication date: 1-Apr-2005. Nadar S, Caine G, Blann A and Lip G (2009) Platelet adhesion in hypertension: Application of a novel assay of platelet adhesion, Annals of Medicine, 10.1080/07853890410018916-1, 37:1, (55-60), Online publication date: 1-Mar-2005. Roldán V and Marín F (2004) Are we content with lowering blood pressure alone, or should we be asking something more from the antihypertensive drugs we use?: effects of antihypertensive agents on fibrinolytic function, Journal of Human Hypertension, 10.1038/sj.jhh.1001754, 18:10, (681-683), Online publication date: 1-Oct-2004. Nadar S, Blann A, Kamath S, Beevers D and Lip G (2004) Platelet indexes in relation to target organ damage in high-risk hypertensive patients, Journal of the American College of Cardiology, 10.1016/j.jacc.2004.03.067, 44:2, (415-422), Online publication date: 1-Jul-2004. Chong A and Lip G (2003) LIFE: losartan versus atenolol, The Lancet, 10.1016/S0140-6736(03)14648-X, 362:9393, (1416), Online publication date: 1-Oct-2003. Tayebjee M, Lee K and Lip G (2003) Salt-loading and nitric oxide inhibition after the menopause, Journal of Hypertension, 10.1097/00004872-200307000-00009, 21:7, (1255-1257), Online publication date: 1-Jul-2003. February 2003Vol 41, Issue 2 Advertisement Article InformationMetrics https://doi.org/10.1161/01.HYP.0000049761.98155.7BPMID: 12574081 Originally publishedFebruary 1, 2003 PDF download Advertisement SubjectsClinical StudiesEndothelium/Vascular Type/Nitric OxideEpidemiologyPlateletsTransplantation" @default.
• W2113048649 created "2016-06-24" @default.
• W2113048649 creator A5050407708 @default.
• W2113048649 date "2003-02-01" @default.
• W2113048649 modified "2023-09-25" @default.
• W2113048649 title "Hypertension, Platelets, and the Endothelium" @default.
• W2113048649 cites W109329984 @default.
• W2113048649 cites W1965127659 @default.
• W2113048649 cites W1972729110 @default.
• W2113048649 cites W1982497683 @default.
• W2113048649 cites W1983338308 @default.
• W2113048649 cites W2046311507 @default.
• W2113048649 cites W2051235217 @default.
• W2113048649 cites W2059806302 @default.
• W2113048649 cites W2093193310 @default.
• W2113048649 cites W2103382606 @default.
• W2113048649 cites W2122719023 @default.
• W2113048649 cites W2124480950 @default.
• W2113048649 cites W2328503656 @default.
• W2113048649 cites W4324263422 @default.
• W2113048649 doi "https://doi.org/10.1161/01.hyp.0000049761.98155.7b" @default.
• W2113048649 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12574081" @default.
• W2113048649 hasPublicationYear "2003" @default.
• W2113048649 type Work @default.
• W2113048649 sameAs 2113048649 @default.
• W2113048649 citedByCount "44" @default.
• W2113048649 countsByYear W21130486492012 @default.
• W2113048649 countsByYear W21130486492015 @default.
• W2113048649 countsByYear W21130486492016 @default.
• W2113048649 countsByYear W21130486492017 @default.
• W2113048649 countsByYear W21130486492018 @default.
• W2113048649 countsByYear W21130486492020 @default.
• W2113048649 countsByYear W21130486492021 @default.
• W2113048649 countsByYear W21130486492022 @default.
• W2113048649 countsByYear W21130486492023 @default.
• W2113048649 crossrefType "journal-article" @default.
• W2113048649 hasAuthorship W2113048649A5050407708 @default.
• W2113048649 hasBestOaLocation W21130486491 @default.
• W2113048649 hasConcept C126322002 @default.
• W2113048649 hasConcept C164705383 @default.
• W2113048649 hasConcept C2776992346 @default.
• W2113048649 hasConcept C71924100 @default.
• W2113048649 hasConcept C89560881 @default.
• W2113048649 hasConceptScore W2113048649C126322002 @default.
• W2113048649 hasConceptScore W2113048649C164705383 @default.
• W2113048649 hasConceptScore W2113048649C2776992346 @default.
• W2113048649 hasConceptScore W2113048649C71924100 @default.
• W2113048649 hasConceptScore W2113048649C89560881 @default.
• W2113048649 hasIssue "2" @default.
• W2113048649 hasLocation W21130486491 @default.
• W2113048649 hasLocation W21130486492 @default.
• W2113048649 hasLocation W21130486493 @default.
• W2113048649 hasOpenAccess W2113048649 @default.
• W2113048649 hasPrimaryLocation W21130486491 @default.
• W2113048649 hasRelatedWork W1904872923 @default.
• W2113048649 hasRelatedWork W1981485427 @default.
• W2113048649 hasRelatedWork W2005348832 @default.
• W2113048649 hasRelatedWork W2013803263 @default.
• W2113048649 hasRelatedWork W2015634999 @default.
• W2113048649 hasRelatedWork W2017873104 @default.
• W2113048649 hasRelatedWork W2035761112 @default.
• W2113048649 hasRelatedWork W2050430854 @default.
• W2113048649 hasRelatedWork W2069419264 @default.
• W2113048649 hasRelatedWork W3142734117 @default.
• W2113048649 hasVolume "41" @default.
• W2113048649 isParatext "false" @default.
• W2113048649 isRetracted "false" @default.
• W2113048649 magId "2113048649" @default.
• W2113048649 workType "article" @default.